Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

gettinricher 11 posts  |  Last Activity: Jun 13, 2016 6:14 PM Member since: Apr 26, 1999
  • Reply to

    Roche Active Today

    by bocamp1 Jun 13, 2016 8:38 AM
    gettinricher gettinricher Jun 13, 2016 6:14 PM Flag

    When Roche has tried to play hardball in the past, they usually end up getting the shaft. The companies go on to make alot of money and do much better than if they had been bought out when they offered. If Roche has learned from their past mistakes, then maybe they will offer what the company will really be worth. They lost billions over the years by playing hardball, and missing the chance to get top notch companies, because they tried to lowball the offers. They would have made a ton more money if the had just offered a fair price in the first place. Maybe they learned and maybe not. I really could care less, if it's Roche or some other company that buy's them. It's Roche who will be paying in the long run....

    Sentiment: Strong Buy

  • Reply to

    Roche Active Today

    by bocamp1 Jun 13, 2016 8:38 AM
    gettinricher gettinricher Jun 13, 2016 2:21 PM Flag

    Why don't you short some more. Seriously, the more the merrier. Roche will need to carp or get off the pot before to longor someone will put in a offer we might take ahead of them. I'm sure they have talked about the possibility of a buyout, but you know Roche will try to lowball them and play the same game they did with Igen by shorting sharesand manipulating the pps lower, (which may be happening again now). BUT, they got caught and ended up with egg on their face. So maybe they learned their lesson, but with this far superior technology they would have to be pretty stupid to let a company like this get away, like Illumina got away before.

    Sentiment: Strong Buy

  • Reply to

    Oh My! Another Big Pop Pooped Out Already

    by educated_wheel Jun 8, 2016 9:32 PM
    gettinricher gettinricher Jun 10, 2016 1:38 PM Flag

    The real GETTINRICHER says, ignore goober and his aliases. Buy while you can, it's still very cheap. Mommy please make them stop calling me mental, It hurts my feelings. Can't you just hear it now. GLTAL's....

    Sentiment: Strong Buy

  • Isn't today the annual shareholder meeting? Maybe somebody will post if any news comes out. Wish I lived closer. GLTAL's.

    Sentiment: Strong Buy

  • Reply to

    Time to buy

    by inder62401 Mar 31, 2016 2:56 PM
    gettinricher gettinricher Apr 22, 2016 1:51 PM Flag

    Don't forget that they come out with the new upgrade in May. Sell at your own peril.

    Sentiment: Strong Buy

  • Wednesday, April 13, 2016

    At Cold Spring Harbor Laboratory, scientists used SMRT® Sequencing to decode one of the most challenging cancer genomes ever encountered. Along the way, they built a portfolio of open-access analysis tools that will help researchers everywhere make structural variation discoveries with long-read sequencing data.

    When Mike Schatz realized a few years ago that his PacBio® System had reached the throughput needed to process human genomes, he decided to give it a real challenge: the incredibly complicated, massively rearranged SK-BR-3 breast cancer cell line. The genome consists of 80 chromosomes, and that’s just the tip of the complexity iceberg.

    “We were really interested in sequencing a human genome that would be maximally impactful and that was aligned with our research interest in cancer genomes, where it’s been well documented that structural variations play a major role,” says Schatz, now an associate research professor of computer science at Johns Hopkins University and an adjunct associate professor of quantitative biology at Cold Spring Harbor Laboratory, where the analysis took place. He notes that despite its importance, structural variation has not been thoroughly studied because short-read sequencers cannot reliably identify these large genomic elements. “One of the really special properties about the PacBio Sequencer is, in addition to being able to call SNPs or small variants, we also get to look for large variants such as structural variation,” he says.

    But as Schatz and his collaborators at Cold Spring Harbor Laboratory and the Ontario Institute for Cancer Research delved into this work, they realized that existing variant callers were tailored to short-read data. To make the most of the large amount of long-read information they were generating, the team wrote a suite of new analysis tools optimized for SMRT Sequencing data. “The tools catering to short-read data just aren’t made to capture the awesome information that we can now take advantage of,” says Maria Nattestad, a graduate student in Schatz’s lab who wrote several of the new algorithms. “Building our own tools was really the only way to go here.”

    Those tools, which are especially important for understanding structural variation, are now being publicly released to fuel further SMRT Sequencing studies of human genomes. Also coming out soon is the team’s detailed analysis of the SK-BR-3 genome and transcriptome, which includes a high-quality assembly as well as a new understanding of gene fusions, the evolutionary history of this cell line, and more.

    De novo sequencing and assembly were the first steps in making sense of the SK-BR-3 genome. With 72-fold SMRT Sequencing coverage, “we got an outstanding assembly of this genome even though it’s so complicated,” Schatz says, citing a contig N50 size of 2.5 Mb compared to a state-of-the-art short-read assembly with a contig N50 of just 3 kb. “That’s nearly a thousand-fold more contiguous going from short-read to long-read assemblies, and it’s through that improved assembly that the majority of structural variants were detected.”

    Using custom-built analysis tools, including variant callers Sniffles, by Schatz lab member Fritz Sedlazeck, and Assemblytics, by Nattestad, the scientists found more than 10,000 structural variants in the SK-BR-3 genome ranging in size from 50 bases to millions of base pairs long. Another major discovery involved meticulously characterizing the complicated process that led to the cell line’s Her2 oncogene amplification.

    The team also used the Iso-Seq™ method to analyze the full transcriptome of SK-BR-3, finding as much complexity at the RNA level as they saw in the DNA. “In the Iso-Seq analysis, we see many tens of thousands of novel isoforms,” Schatz says. “That’s a really strong testament to the long reads, which fully capture an isoform in one sequence — unlike short reads, where you have to infer isoform structure.”

    To learn more about the project, which included novel findings about gene fusions in cancer, check out the full case study.

    Sentiment: Strong Buy

  • Reply to

    Nice Interview

    by officegirl53 Apr 12, 2016 1:52 PM
    gettinricher gettinricher Apr 13, 2016 1:00 PM Flag

    When you say (he), you should just say (you). You are not fooling anybody. Why do you waste your life bashing this stock with all your aliases. It is not going to keep the stock from taking off when it's ready, and we are getting very close to seeing many high volume, high price increase days ahead. This has been in the works for awhile now, and it's getting ready to start paying the shareholders off. If you need another alias, how about (Board idiot). We've been calling you that for along time now, and it fits you to a T. GLTAL's....

    Sentiment: Strong Buy

  • Reply to

    Nice Interview

    by officegirl53 Apr 12, 2016 1:52 PM
    gettinricher gettinricher Apr 13, 2016 10:44 AM Flag

    How many aliases you need moron? You said once we hit .50 again you would leave right? I think you are just making up new aliases, then just abandon your old wore out ones. (Just like this one). How about (the copycatter). That seems to fit. IDIOT

    Sentiment: Strong Buy

  • gettinricher by gettinricher Apr 5, 2016 1:38 PM Flag

    Mark this, as the day the company will really start pulling in customers, and grabs the attention of any and all in this field. After a short time now, the price will blast through .50 where the board idiot/troll said he would leave and not return. The wait has paid off. OH HAPPY DAYS......

    Sentiment: Strong Buy

  • Reply to

    Becareful Trap

    by arkadykiv Apr 1, 2016 10:23 AM
    gettinricher gettinricher Apr 1, 2016 10:58 AM Flag

    That's what they set you up for, but sometimes their plans get foiled and big buyer decides it's time to load up and it ruins their plans. Hopefully today we will hold these gains and continue to add on going into the earnings and cc. Like I said earlier, these manipulated moves mean nothing. It's the huge volume days on news that will really wake up the investor and scientific community that will take us to the promised land. GLTAL's.

    Sentiment: Strong Buy

  • Reply to

    Becareful Trap

    by arkadykiv Apr 1, 2016 10:23 AM
    gettinricher gettinricher Apr 1, 2016 10:45 AM Flag

    This company is only just getting started. Second half of this year will be a full out sales blast with Roche leading the way. We are on the same trajectory as Illumina, but our technology is far superior, and long reads are going to put the short read companies out of business. And with prices coming down so quickly, as to make long reads close in price to short reads, then long reads will be almost solely used instead of short reads. If PACB doesn't get bought out and they are allowed to be an ongoing company, then the pps will also explode upward over the next few years. So these day to day ups and downs are really irrelavant anyway.

    Sentiment: Strong Buy

SNY
38.45-2.74(-6.65%)Jun 24 4:02 PMEDT